Back to top
more

IM Cannabis (IMCC)

(Delayed Data from NSDQ)

$0.55 USD

0.55
250,522

-0.01 (-2.12%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.55 0.00 (-0.87%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IM Cannabis (IMCC) Expands Business in Germany With New Alliance

by Zacks Equity Research

The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.

Warby Parker Inc. (WRBY) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Warby Parker Inc. (WRBY) delivered earnings and revenue surprises of 100% and 2.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Verano Holdings Corp. (VRNOF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of -100% and 1.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Beats Q2 Earnings Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 21.29% and 2.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 63.16% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of -157.01% and 81.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.53% and 4.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 13.86% and 7.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Leafly Holdings, Inc. (LFLY) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Leafly Holdings, Inc. (LFLY) delivered earnings and revenue surprises of -6.25% and 0.68%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

IM Cannabis Corp. (IMCC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of 16.67% and 45.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of 38.46% and 32.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (VAPO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vapotherm (VAPO) delivered earnings and revenue surprises of -16.88% and 19.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IM Cannabis Corp. (IMCC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of -700% and 8.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Senestech, Inc. (SNES) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Senestech, Inc. (SNES) delivered earnings and revenue surprises of -10.53% and 24.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Abbott (ABT): Can Its 3.1% Jump Turn into More Strength?

by Zacks Equity Research

Abbott (ABT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

IM Cannabis Corp. (IMCC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of -550% and 6.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) Q1 Earnings Top Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 22.22% and 4.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 37.50% and 11.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (VAPO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vapotherm (VAPO) delivered earnings and revenue surprises of -38.10% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of -8.33% and 4.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in the Pharmaceutical segment.